OTCMKTS:PXRB - Pixarbio Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.01 0.00 (0.00 %)
(As of 03/19/2019 01:39 AM ET)
Previous Close$0.01
Today's Range$0.01 - $0.01
52-Week Range$0.0010 - $1.00
Volume2,500 shs
Average VolumeN/A
Market Capitalization$815,000.00
P/E RatioN/A
Dividend YieldN/A
PixarBio Corporation, a specialty pharmaceutical/biotechnology company, focuses on the pre-clinical and clinical development of neurological drug delivery systems for post-operative pain. The company researches and develops delivery systems for drugs, devices, or biologics to treat pain, epilepsy, epilepsy, Parkinson's disease, and spinal cord injury. Its principal product platform is NeuroRelease for the therapeutic release of non-opiate drugs for post-operative, acute, and chronic pain in pre-clinical models. The company is based in Medford, Massachusetts.

Receive PXRB News and Ratings via Email

Sign-up to receive the latest news and ratings for PXRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:PXRB



Sales & Book Value

Annual Sales$1.97 billion



Market Cap$815,000.00
Next Earnings DateN/A
OptionableNot Optionable

Pixarbio (OTCMKTS:PXRB) Frequently Asked Questions

What is Pixarbio's stock symbol?

Pixarbio trades on the OTCMKTS under the ticker symbol "PXRB."

Has Pixarbio been receiving favorable news coverage?

Media coverage about PXRB stock has been trending somewhat positive on Monday, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pixarbio earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are some of Pixarbio's key competitors?

What other stocks do shareholders of Pixarbio own?

Who are Pixarbio's key executives?

Pixarbio's management team includes the folowing people:
  • Mr. Francis M. Reynolds, Co-Founder, Chairman, CEO, CFO, Chief Scientific Officer & Corp. Sec. (Age 56)
  • Dr. Jason Criscione, Co-Founder and Chief Technology Officer (Age 37)
  • Dr. Amer Khalil, Co-Founder, MD & Member of Scientific Advisory Board
  • Mr. Haining Dai, Co-Founder & Director of Preclinical Neuroscience
  • Ms. Xi Chen, Co-Founder & Director of Analytical Chemistry

How do I buy shares of Pixarbio?

Shares of PXRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pixarbio's stock price today?

One share of PXRB stock can currently be purchased for approximately $0.01.

How big of a company is Pixarbio?

Pixarbio has a market capitalization of $815,000.00 and generates $1.97 billion in revenue each year.

What is Pixarbio's official website?

The official website for Pixarbio is http://www.buddhimatyoga.com.

How can I contact Pixarbio?

Pixarbio's mailing address is 200 BOSTON AVE. STE. 1875, MEDFORD MA, 02155. The company can be reached via phone at 617-803-8838 or via email at [email protected]

MarketBeat Community Rating for Pixarbio (OTCMKTS PXRB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  35
MarketBeat's community ratings are surveys of what our community members think about Pixarbio and other stocks. Vote "Outperform" if you believe PXRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PXRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: What is a Stop Order?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel